Literature DB >> 16439367

Phosphorylation of the hinge domain of the nuclear hormone receptor LRH-1 stimulates transactivation.

Yoon-Kwang Lee1, Yun-Hee Choi, Steven Chua, Young Joo Park, David D Moore.   

Abstract

The nuclear receptor LRH-1 (NR5A2) functions to regulate expression of a number of genes associated with bile acid homeostasis and other liver functions, but mechanisms that modulate its activity remain unclear. We have found that mitogenic stimuli, including treatment with phorbol myristate (PMA), increase LRH-1 transactivation. This response maps to the hinge and ligand binding domains of LRH-1 and is blocked by the mitogen-activated protein kinase ERK1/2 inhibitor U0126. LRH-1 is a phosphoprotein and hinge domain serine residues at 238 and 243 are required for effective phosphorylation, both in vitro and in cells. Preventing phosphorylation of these residues by mutating both to alanine decreases PMA-dependent LRH-1 transactivation and mimicking phosphorylation by mutation to positively charged aspartate residues increases basal transactivation. Although serine phosphorylation of the hinge of SF-1 (NR5A1), the closest relative of LRH-1, confers a similar response, the specific targets differ in the two closely related orphan receptors. These results define a novel pathway for the modulation of LRH-1 transactivation and identify specific LRH-1 residues as downstream targets of mitogenic stimuli. This pathway may contribute to recently described proliferative functions of LRH-1.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16439367     DOI: 10.1074/jbc.M509115200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  30 in total

Review 1.  Aromatase, breast cancer and obesity: a complex interaction.

Authors:  Serdar E Bulun; Dong Chen; Irene Moy; David C Brooks; Hong Zhao
Journal:  Trends Endocrinol Metab       Date:  2011-12-12       Impact factor: 12.015

Review 2.  Emerging actions of the nuclear receptor LRH-1 in the gut.

Authors:  Pablo J Fernandez-Marcos; Johan Auwerx; Kristina Schoonjans
Journal:  Biochim Biophys Acta       Date:  2010-12-29

3.  ERK/MAPK regulates ERRγ expression, transcriptional activity and receptor-mediated tamoxifen resistance in ER+ breast cancer.

Authors:  Mary M Heckler; Hemang Thakor; Cara C Schafer; Rebecca B Riggins
Journal:  FEBS J       Date:  2014-04-28       Impact factor: 5.542

Review 4.  Cell signaling and nuclear receptors: new opportunities for molecular pharmaceuticals in liver disease.

Authors:  Jeff L Staudinger; Kristin Lichti
Journal:  Mol Pharm       Date:  2007-12-27       Impact factor: 4.939

Review 5.  Extra-adrenal glucocorticoid synthesis in the intestinal epithelium: more than a drop in the ocean?

Authors:  Mario Noti; Daniel Sidler; Thomas Brunner
Journal:  Semin Immunopathol       Date:  2009-06-03       Impact factor: 9.623

Review 6.  Hepatic glucose sensing and integrative pathways in the liver.

Authors:  Maaike H Oosterveer; Kristina Schoonjans
Journal:  Cell Mol Life Sci       Date:  2013-11-07       Impact factor: 9.261

7.  The nuclear hormone receptor family member NR5A2 controls aspects of multipotent progenitor cell formation and acinar differentiation during pancreatic organogenesis.

Authors:  Michael A Hale; Galvin H Swift; Chinh Q Hoang; Tye G Deering; Toshi Masui; Youn-Kyoung Lee; Jumin Xue; Raymond J MacDonald
Journal:  Development       Date:  2014-07-25       Impact factor: 6.868

8.  The pERK of being a target: Kinase regulation of the orphan nuclear receptor ERRγ.

Authors:  Rebecca B Riggins
Journal:  Receptors Clin Investig       Date:  2014

Review 9.  Minireview: physiological and pathological actions of RAS in the ovary.

Authors:  Heng-Yu Fan; Joanne S Richards
Journal:  Mol Endocrinol       Date:  2009-10-30

10.  Nuclear receptor liver receptor homologue 1 (LRH-1) regulates pancreatic cancer cell growth and proliferation.

Authors:  Cindy Benod; Maia V Vinogradova; Natalia Jouravel; Grace E Kim; Robert J Fletterick; Elena P Sablin
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-26       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.